Aarti Drugs Limited

rs,

o.:L37060MH1984PLC055433 To, Listing/ Compliance Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 BSE CODE: 524348 Dear Sir/Madam, To, Listing/ Compliance Depar

Rs. 100 crore

isted On National Stock Exchange of India Limited 2017 Pinnacle Life Science Pvt. Ltd. crossed Rs. 100 crores turnover 2014 2022 Consolidated Revenue Rs. 2,500 Cr 2020 Crossed Rs. 2,000 Cr Consoli

Rs. 2,500

nacle Life Science Pvt. Ltd. crossed Rs. 100 crores turnover 2014 2022 Consolidated Revenue Rs. 2,500 Cr 2020 Crossed Rs. 2,000 Cr Consolidated Turnover & Rs. 200 Cr Formulations Turnover Crosse

Rs. 2,000

rossed Rs. 100 crores turnover 2014 2022 Consolidated Revenue Rs. 2,500 Cr 2020 Crossed Rs. 2,000 Cr Consolidated Turnover & Rs. 200 Cr Formulations Turnover Crossed Rs. 200 Cr consolidated PAT

Rs. 200

2022 Consolidated Revenue Rs. 2,500 Cr 2020 Crossed Rs. 2,000 Cr Consolidated Turnover & Rs. 200 Cr Formulations Turnover Crossed Rs. 200 Cr consolidated PAT Crossed Rs. 1,000 crores turnover

Rs. 200

2020 Crossed Rs. 2,000 Cr Consolidated Turnover & Rs. 200 Cr Formulations Turnover Crossed Rs. 200 Cr consolidated PAT Crossed Rs. 1,000 crores turnover formulation Entered through 100% subs

Rs. 1,000 crore

dated Turnover & Rs. 200 Cr Formulations Turnover Crossed Rs. 200 Cr consolidated PAT Crossed Rs. 1,000 crores turnover formulation Entered through 100% subsidiary - Pinnacle Life Science Pvt. Ltd. 19

100%

d Rs. 200 Cr consolidated PAT Crossed Rs. 1,000 crores turnover formulation Entered through 100% subsidiary - Pinnacle Life Science Pvt. Ltd. 1998 Crossed Rs. 100 crores turnover 4 1996

Rs. 100 crore

formulation Entered through 100% subsidiary - Pinnacle Life Science Pvt. Ltd. 1998 Crossed Rs. 100 crores turnover 4 1996 Amalgamation of Rupal Chemical Industries Ltd, Rashesh Chemicals & Pharmac

4,077 MT

Manufacturing Largest producer of Ketoconazole in the world 12 Manufacturing Facilities 4,077 MT/Monthly Capacity 80+ Finished Products 1,10,330 Sq.m Plant Area Largest producer of Metr

37%

Sq.m Plant Area Largest producer of Metronidazole Benzoate in the world ~1,450 Employees ~37% Export Revenue Largest producer in Fluoroquinolones group in the world Largest producer of

12%

e in 100+ Countries across 6 Continents ensures diversification and risk minimization Europe 12% FY21 12% FY22 Africa 6% FY21 7% FY22 Asia 58% FY21 54% FY22 North America 1

Revenue

1

Captive consumption

1

Captive consumption

Rs. 300 crores Revenue Growth Higher Margins Higher RoCE 10 11 Financial Highlights of FY22 and Q1FY23 FY 22 Result Highlights Rs. crores Revenue EBITDA & EBITDA Margin (%) PAT & PAT Margin (%) 20.5% 13.7% 13.0% 8.2% +16% 2,500 442 280 2,159 341 205 FY21 FY22 FY21 FY22 FY21 FY22 1. 2. EBITDA includes other income & excludes exceptional items Exceptional items includes profit on sale of assets of Rs. 8.38 crores in Q4FY20, excluding exceptional items, PAT grew 2.3% YoY 13 Q1FY23 Result Highlights Rs. crores Revenue EBITDA & EBITDA Margin (%) PAT & PAT Margin (%) 14.0% 12.8% 10.8% 8.4% 8.0% 5.6% 694 89 622 81 580 67 55 49 35 Q1 FY22 Q4 FY22 Q1 FY23 Q1FY22 Q4 FY22 Q1 FY23 Q1 FY22 Q4 FY22 Q1 FY23 1. EBITDA includes other income & excludes exceptional items 14 FY22 Segmental Break-up FY21 FY22 79% 13% 4% 4% 80% 11% 4% 5% API Formulation Speciality Chemicals Intermediates & Others API Formulation Speciality Chemicals Intermediates & Others 15 16 Historical Performance At A Glance Strong Fina